If you’ve struggled with stomach issues in the past, you may recognize the bacteria Helicobacter pylori as a main cause of the problem. But did you know that H. pylori can also cause gastric cancer, non-alcoholic fatty liver disease, and coronary heart disease?
A clinical study in Japan offers valuable insights into the connection between inflammatory markers throughout the body and the damage they can cause if left untreated. This study found that inhibiting H. pylori bacteria also reduced the risk of heart disease.
This is because H. pylori bacteria causes inflammation. And this inflammation doesn’t just affect the stomach lining – it can cause trouble throughout the body, lowering levels of good HDL cholesterol, unhealthy cell development, and elevated white cell counts that try to fight an invasive situation.
By the end of the study, white cell counts were significantly less in those who’d been treated for H. pylori, which is understandable: the bacteria was gone and no longer needed the vigilance of the immune system. But what was also interesting is that the HDL levels rose significantly, too. By reducing one cause of inflammation and disease that normally affects the digestive system, the heart is made stronger, too.
One way of battling ulcers, acid reflux, or other digestive disorders that cause inflammation is with an extract of licorice called “deglycyrrhizinated licorice,” or DGL. This kind of licorice has had the glycyrrhizin removed, which in some individuals, taken in very high amounts, could elevate blood pressure.
DGL helps protect the stomach and intestinal lining and is an extremely powerful, natural medicine. If you’re already familiar with DGL in its traditional, chewable form and found the licorice taste unpleasant, there is a clinically-studied capsule form that provides all of the benefits without the need to chew it first.
Iwai N, Okuda T, Oka K, et al. Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study. PLoS One. 2019 Aug 16;14(8):e0221349.
BACKGROUND: Extra-gastric manifestation of Helicobacter pylori infection involves systemic inflammation, which results in the production of several cytokines. Only a few clinical trials have investigated the effect of H. pylori eradication therapy on lipid metabolism in the infected patients with chronic gastritis. We aimed to evaluate the effect of H. pylori eradication therapy on lipid metabolism in a Japanese population with chronic gastritis.
METHODS: One hundred and sixty-three patients with H. pylori-associated chronic gastritis were enrolled in this study between June 2015 and March 2017. They underwent H. pylori eradication therapy; the effects of the therapy were assessed by the urea breath test performed at least 4 weeks after the therapy. After confirming H. pylori eradication, the health screening examination was repeated between May 2016 and August 2018. The clinical parameters were compared before and after the administration of the eradication therapy.
RESULTS: The mean age of the enrolled patients was 56.7 years, and the mean follow-up duration was 514.7 days. Weight, body mass index, and obesity index were significantly increased post-eradication therapy compared to those pre-eradication therapy. White blood cell and platelet counts were significantly decreased, and high density lipoprotein cholesterol (HDL) level was significantly increased (P = 0.001), while low density lipoprotein cholesterol (LDL), total cholesterol, and triglycerides levels were not altered significantly. Hence, the LDL/HDL ratio was significantly decreased.
CONCLUSIONS: This study reported that H. pylori eradication therapy increase the HDL levels in the infected patients with chronic gastritis. Hence, the LDL/HDL ratio, which is used to evaluate the risk of atherosclerosis, was significantly decreased post-eradication therapy compared to that pre-eradication therapy.
Follow this link for the complete article: Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study
[Choose from topics below to personalize articles fed to your home page]